Exchange: NASDAQ·Updated 01:12 PM EDT
News
all
press releases
BioAge Labs, Inc. (BIOA) Reports Q2 Loss, Beats Revenue Estimates
BioAge Labs, Inc. (BIOA) delivered earnings and revenue surprises of +10.77% and +172.33%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
More News
BIOA, GLUE Stocks Clock Worst Day In Years— What’s The NVO Connection?
BIOA clocked its worst day since December 2024 on Friday, while GLUE booked its worst day ever.
Stocktwits
Is BioAge Labs, Inc. (BIOA) Stock Positioned for Growth With New Phase 2 Cardiovascular Study Initiation?
Is BioAge Labs, Inc. (BIOA) Stock Positioned for Growth With New Phase 2 Cardiovascular Study Initiation...
Yahoo! Finance: News
Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets
Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets PR Newswire NEW YORK, May 20, 2026 Cell therapies and precision biologics are driving new...
PR Newswire
A Unique Klotho-based Anti-Aging Therapy to Be Introduced at a Premier Longevity Forum: Inside Ava Bio's Cell-Based Platform Approach
A Unique Klotho-based Anti-Aging Therapy to Be Introduced at a Premier Longevity Forum: Inside Ava Bio's Cell-Based Platform Approach A Unique Klotho-based Anti-Aging Therapy to Be Introduced at a...
PR Newswire
BioAge Labs (NASDAQ:BIOA) Trading 8.6% Higher - Here's Why
BioAge Labs (NASDAQ:BIOA) Shares Up 8.6% - What's Next...
MarketBeat
Wall Street Zen Downgrades BioAge Labs (NASDAQ:BIOA) to Sell
Wall Street Zen downgraded BioAge Labs from a "hold" rating to a "sell" rating in a research report on Saturday...
MarketBeat
BioAge Labs Touts Phase 1 BGE-102 Data, Citing 86% hs-CRP Drop and Clean Safety Profile
BioAge Labs (NASDAQ:BIOA) executives outlined phase I results for its oral, brain-penetrant NLRP3 inhibitor BGE-102, highlighting what the company characterized as deep reductions in inflammatory...
MarketBeat
Has Amarin (AMRN) Outpaced Other Medical Stocks This Year?
Here is how Amarin (AMRN) and BioAge Labs, Inc. (BIOA) have performed compared to their sector so far this year.
Zacks
BioAge Labs (NASDAQ:BIOA) Stock Price Down 6.1% - Time to Sell?
BioAge Labs (NASDAQ:BIOA) Trading Down 6.1% - What's Next...
MarketBeat

Advertisement|Remove ads.